Every Form 4 that Protagonist Ther (PTGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTGX filings page.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported option exercises and share sales in August 2026 under a Rule 10b5-1 trading plan adopted on January 30, 2026. He exercised stock options for 100,000 shares of common stock at an exercise price of $21.58 per share and sold the resulting 100,000 shares in open-market transactions at weighted average prices of $149.11 on August 10 and $148.52 on August 11. The options exercised were fully vested and were scheduled to expire on October 11, 2026.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 9,000 shares of common stock at $16.54 per share and sold 9,000 shares at a weighted average price of $117.94 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance. After the transactions, he directly owns 7,825 shares of common stock.
Protagonist Therapeutics director William D. Waddill exercised stock options for 9,000 shares of common stock at strike prices of $16.54 and $11.80, then sold 9,000 shares in an open-market transaction at a weighted average price of $107.68 under a pre-arranged Rule 10b5-1 trading plan, leaving him with 7,825 shares held directly.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction. He exercised 9,000 shares of Common Stock at $11.80 per share, then sold 9,000 shares in an open-market sale at $99.64 per share.
After these transactions, he directly holds 7,825 shares of Common Stock and 3,000 stock options remain outstanding, with the options expiring on June 6, 2029. The filing notes the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock. On May 12, 2026, he exercised stock options for 75,000 shares at $21.58 per share and sold 75,000 shares in open-market trades at a weighted average price of $100.12 per share, with individual sale prices ranging from $98.83 to $103.50. After these transactions, he directly holds 523,478 common shares. The filing notes the actions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026, and that the related stock options are fully vested and expire on October 11, 2026, with 225,000 options reported as remaining outstanding.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 75,000 shares of common stock at an exercise price of $21.58 per share, then sold 75,000 shares in an open-market transaction at a weighted average price of $100.12 per share across multiple trades ranging from $98.83 to $103.50. Following these transactions, he directly holds 523,478 shares of common stock. The exercised stock options were fully vested and are scheduled to expire on October 11, 2026.
Protagonist Therapeutics director Bryan Giraudo reported exercising stock options and selling shares of common stock. On May 7, he exercised options for 36,000 shares at exercise prices of $6.45 and $6.98 per share and sold 36,000 directly held shares at about $100.14 per share. The Bryan & Courtney Giraudo Trust sold an additional 12,000 shares that day at about $100.07 per share.
On May 8, Giraudo sold 5,130 directly held shares at $100.00 per share, and the trust sold another 6,000 shares at $100.00 per share. A footnote states these sales occurred at prices ranging from $98.69 to $104.67. After these transactions, he holds 12,695 shares of Protagonist Therapeutics common stock directly, and the trust no longer holds shares from these reported transactions. All reported stock options are shown as fully exercised, with no remaining derivative holdings in this filing.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel, Ph.D. reported a bona fide gift of 1,460 shares of Common Stock to family and friends. The transaction carried a reported price of $0.00 per share, reflecting that no sale proceeds were received.
Following this gift transfer, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock. The filing shows no option exercises or open-market purchases or sales in this transaction, only the non-cash gift disposition.
Protagonist Therapeutics Chief Financial Officer Ali Asif reported an open-market sale of 1,750 shares of common stock at $105.47 per share on April 20, 2026. According to the filing, the sale was made to cover tax withholding obligations triggered by the settlement of restricted stock units.
After this transaction, Asif directly holds 59,003 shares of Protagonist Therapeutics common stock, indicating that the sale represents a small portion of his overall reported holdings.
Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.
Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.
On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.
Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock. On March 24–25, he exercised stock options covering 54,700 shares of Common Stock at an exercise price of $8.58 per share and acquired the same number of shares.
He then sold 54,700 Common Stock shares in open-market transactions at $101.00 per share. On March 23, he made a bona fide gift of 50,000 Common Stock shares to relatives. Following these transactions, Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock.
Protagonist Therapeutics (PTGX) director Williams Lewis T reported exercising stock options and selling shares. On February 17, 2026, he exercised 18,000 stock options at a price of $10.84 per share, converting them into 18,000 shares of common stock. The options are fully vested.
That same day, he sold 18,000 common shares in open-market transactions at a weighted average price of $82.42 per share, with individual trade prices ranging from $81.47 to $83.12. After these transactions, he directly holds 7,825 common shares and 6,000 stock options.
Protagonist Therapeutics director William D. Waddill reported an option exercise and share sale on February 6, 2026. He exercised 20,000 stock options at an exercise price of $8.31 per share and acquired 20,000 common shares.
On the same date, he sold 20,000 common shares at a weighted average price of $83.68 per share, in multiple trades between $83.65 and $83.87. After these transactions, he directly owned 7,825 shares of common stock, and the reported stock options were fully exercised with 0 options remaining.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported multiple stock transactions in January 2026. On January 23, 2026, he made a charitable donation of 6,000 shares of common stock to a donor-advised fund for charitable purposes.
Across January 23–27, 2026, he exercised vested stock options to acquire common shares at exercise prices of $4.21 and $21.58 per share and sold matching share amounts in open-market transactions at reported weighted average sale prices of $84.59, $84, $84.05 and $83.19 per share.
Following these transactions, he directly owned 574,505 shares of common stock and held 300,000 stock options with exercise price $21.58 expiring on October 11, 2026 and 10,685 stock options with exercise price $4.21 expiring on April 29, 2026.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported multiple stock transactions on January 27, 2026. He exercised stock options for 16,000 common shares at $19.19 and 12,000 shares at $12.17, then sold 28,000 shares at a weighted average price of $83.13 and 18,203 shares at $83.14. After these transactions, he directly owned 60,320 common shares. The exercised options relate to grants from April 18, 2022 and January 16, 2023, which vest over time subject to his continued service.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported multiple stock option exercises and share sales. On January 26 and 27, 2026, he exercised a total of 10,000 stock options at an exercise price of $8.04 per share and acquired the same number of common shares.
He then sold 5,000 shares on each of January 26 and 27 at weighted average prices of $82.28 and $82 per share, and earlier sold 13,151 shares on January 23, 2026 at a weighted average price of $82.42 per share. After these transactions he directly owned 84,115 common shares and 65,971 stock options, with the option grant originally covering 127,500 shares and vesting through November 7, 2026.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported a sale of company stock. On January 20, 2026, he sold 9,514 shares of Common Stock at a price of $82.48 per share. The filing explains that this sale was made to cover the tax withholding obligation incurred when restricted stock units settled, meaning the transaction was tied to taxes rather than an open-market portfolio decision. After this sale, Molina beneficially owned 97,266 shares of Protagonist Therapeutics common stock in direct form.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported a sale of company common stock in a Form 4 filing. On January 20, 2026, he sold 34,438 shares of Protagonist Therapeutics common stock at a price of $82.48 per share, reported as a direct ownership transaction.
According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was tied to an equity award rather than an open-market discretionary sale of his broader holdings. After this transaction, Patel directly beneficially owned 580,505 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported a sale of common stock in a Form 4 filing. On January 20, 2026, he sold 8,588 shares of Protagonist Therapeutics common stock at a price of $82.48 per share. According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was connected to equity compensation rather than a discretionary open-market sale. After this transaction, Ali beneficially owns 78,077 shares of the company’s common stock directly.
Protagonist Therapeutics director Harold E. Selick reported exercising a stock option on 01/09/2026, converting 14,299 stock options with an exercise price of $4.21 into 14,299 shares of common stock. The transaction is coded “M,” indicating an option exercise.
Following this transaction, Selick directly beneficially owns 60,845 shares of Protagonist Therapeutics common stock. The filing notes that the stock options exercised were fully vested and that no derivative securities of this option grant remain outstanding.
Protagonist Therapeutics director William D. Waddill reported new equity awards from the company. On January 2, 2026, he received 2,695 restricted stock units of common stock at a price of $0, bringing his directly held common stock to 7,825 shares after the grant. These restricted stock units vest in full on January 15, 2027, as long as he continues serving the company.
He also received a stock option for 3,762 shares of common stock with an exercise price of $87.18 per share. The option vests in 12 equal monthly installments following January 2, 2026, subject to his continued service, and expires on January 2, 2036. Both awards are reported as directly owned.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported equity awards on Form 4. On January 2, 2026, he received 95,400 shares of common stock as a grant of restricted stock units at a stated price of $0. These units are payable solely in common stock and will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, contingent on his continued service.
On the same date he was also granted a stock option for 120,200 shares of common stock with an exercise price of $87.18. This option vests in 48 equal monthly installments following January 2, 2026, also subject to continued service, and had 120,200 derivative securities beneficially owned after the transaction. Following the restricted stock grant, he beneficially owned 614,943 shares of common stock directly.
Protagonist Therapeutics, Inc. (PTGX) reported an insider equity change involving its President and CEO, who is also a director. On 11/21/2025, the reporting person made a bona fide gift of 440 shares of common stock, identified with transaction code "G" for a gift. The filing notes that the gift was made to the reporting person’s grandchild.
Following this gift transaction, the reporting person beneficially owns 519,543 shares of PTGX common stock, held directly. This Form 4 reflects a personal, non-sale transfer and does not describe any purchase or sale of shares on the market.
Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer. On 11/17/2025, Chief Medical Officer Arturo Molina reported selling 2,712 shares of common stock at a price of $84.77 per share. The sale was made to cover tax withholding obligations incurred when restricted stock units settled, rather than as an open-market discretionary sale.
Following this transaction, Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock in direct form. The filing was made by a single reporting person and does not list any derivative securities transactions.
Protagonist Therapeutics (PTGX) director William D. Waddill exercised 12,000 stock options at $6.98 on 10/10/2025 and sold 12,000 shares the same day pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2023.
Sales included 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average, with individual trades ranging from $86.71 to $88.00. Following these transactions, he directly holds 5,130 shares. The exercised options were fully vested and were set to expire on 05/28/2028.
Protagonist Therapeutics director William D. Waddill sold 4,000 shares of Protagonist Therapeutics, Inc. (PTGX) common stock on 09/22/2025 at a price of $64.25 per share, leaving him with 5,130 shares beneficially owned following the transaction. The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on November 10, 2023. The Form 4 was signed on behalf of Mr. Waddill by an attorney-in-fact on 09/24/2025. The filing reports the transaction as a non-derivative disposition by a director and indicates the Form was filed by one reporting person.
Dinesh V. Patel, Ph.D., President and CEO and director of Protagonist Therapeutics, Inc. (PTGX), reported a change in beneficial ownership on Form 4. The filing discloses a transaction dated 09/16/2025 in which Dr. Patel made a bona fide gift of 620 shares of the issuer's common stock to his son at a reported price of $0 (coded G). After the reported transaction, Dr. Patel beneficially owned 519,983 shares, held directly. The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dr. Patel.